Therefore, while it is generally accepted that histones macroH2A1.1 and macroH2A2 act as tumour suppressors, macroH2A1.2 variant seems to be an oncogene associated with disease progression and negative patient outcome. This evidence concerns the gene MACROH2A1 and neoplasm.